| 1 |
31586300 | mTOR inhibitor everolimus reduces invasiveness of melanoma cells. | 2020 Jan |
1 |
| 2 |
31732523 | Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. | 2020 Jan 1 |
3 |
| 3 |
31736196 | Sensitization of HT29 colorectal cancer cells to vemurafenib in three-dimensional collagen cultures. | 2020 Feb |
1 |
| 4 |
31758648 | Role of VEGFR-1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib. | 2020 Jan |
1 |
| 5 |
31819183 | Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells. | 2020 Jan |
5 |
| 6 |
31833658 | Metabolic imaging using hyperpolarized 13 C-pyruvate to assess sensitivity to the B-Raf inhibitor vemurafenib in melanoma cells and xenografts. | 2020 Jan |
1 |
| 7 |
31911278 | VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer. | 2020 Feb |
6 |
| 8 |
31922436 | Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines. | 2020 Apr |
2 |
| 9 |
32026754 | Cell-free DNA BRAF V600E measurements during BRAF inhibitor therapy of metastatic melanoma: long-term analysis. | 2020 Feb 6 |
2 |
| 10 |
32029534 | Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers. | 2020 May |
1 |
| 11 |
32043767 | Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease. | 2020 Feb |
2 |
| 12 |
32053122 | Induced sarcoid-like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: a monocentric retrospective study. | 2020 Jun |
1 |
| 13 |
32066648 | Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration. | 2020 Feb |
1 |
| 14 |
31597857 | [Status of Langerhans cell histiocytosis in children and adults]. | 2019 |
2 |
| 15 |
31666812 | Primary oral manifestation of Langerhans cell histiocytosis refractory to conventional therapy but susceptible to BRAF-specific treatment: a case report and review of the literature. | 2019 |
1 |
| 16 |
31672130 | Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting. | 2019 Oct 31 |
2 |
| 17 |
31726389 | A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein. | 2019 Dec 6 |
2 |
| 18 |
31938368 | Targeting STAT3 restores BRAF inhibitor sensitivity through miR-759-3p in human cutaneous melanoma cells. | 2018 |
1 |